Brandys Nad Labem

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 5 Obesity
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting
  2025-524265-24-00 5 2026-05-21 Dyslipidemia at High to Very High Cardiovascular Risk
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting
  2025-523975-48-00 5 2026-05-08 Obesity
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D … Recruiting
  2025-523123-22-00 5 2026-05-07 Chronic Kidney Disease
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting
  2024-517866-40-00 4 2025-09-29 Moderate-to-severe Asthma
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio … Recruiting
  2024-519525-38-00 5 2025-08-22 Heart failure
• A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Parti … Recruiting
  2024-517991-39-00 5 2025-07-22 Asthma
• A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien … Recruiting
  2024-519059-28-00 5 2025-07-17 Chronic Heart Failure
• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona … Recruiting
  2024-517458-90-00 5 2025-06-06 Chronic obstructive pulmonary disease (COPD)
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerabilit … Recruiting
  2023-504835-42-00 4 2024-02-29 Heart Failure (Heart Failure with Reduced Ejection Fraction)
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab … Recruiting
  2023-503224-66-00 5 2023-10-31 Atrial Fibrillation
• A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended recruitment
  2025-520521-21-00 5 2025-09-02 Hyperlipidemia
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A Phase 2, Double-blind, Placebo-controlled, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Ended recruitment
  2023-508039-29-00 4 2024-09-16 Moderate-to-severe Asthma
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)

Showing 1–24 of 50 trials